Targeted therapy for patients with unresectable stage III lung cancer and rare mutations

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This umbrella trial utilizes next generation sequencing (NGS) to identify patients with treatment-naive unresectable stage III non-small-cell lung cancer (NSCLC) that harbor rare mutations. The study aims to evaluate the efficacy of NGS-directed targeted therapies, such as Sunvozertinib and Crizotinib, followed by surgical intervention. Given the challenges posed by the heterogeneity of stage III NSCLC, this approach seeks to provide a tailored treatment strategy for patients who may not benefit from conventional therapies. The trial focuses on patients whose tumors do not have common EGFR mutations, thereby exploring alternative therapeutic avenues.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Subjects must have treatment-naive unresectable stage III NSCLC according to the AJCC 8th edition staging;
* Squamous or non-squamous NSCLC histology;
* Subjects should have a rare mutation based on NGS, including mutations of EGFR exon20ins, ROS1 fusion, RET fusion, NTRK fusion, MET 14 exon, HER2, BRAF V600E, KRAS G12C, and ALK fusion.
* Subjects should be without EGFR exon 19 deletions or exon 21 L858R activating mutation;
* Male and female, aged 18-75 years;
* Blood and specimens before and after treatment must be provided;
* Eastern Cooperative Oncology Group (ECOG) performance status of 0-1;
* Adequate hematological function: Absolute neutrophil count (ANC) ≥2.0 x 109/L, and Platelet count ≥100 x 109/L, and Hemoglobin ≥9 g/dL (may be transfused to maintain or exceed this level);
* Adequate liver function: Total bilirubin ≤ 1.5 x upper limit of normal (ULN), Aspartate aminotransferase (AST), alanine aminotransferase (ALT) ≤ 2.5 x ULN;
* Adequate renal function: Serum creatinine ≤ 1.25 x ULN, or ≥ 60 ml/min;
* Female subjects should not be pregnant or breast-feeding;
* Written informed consent provided. Being willing and able to comply with the visits, treatment plan, laboratory examinations and other study procedures scheduled in the study.

Exclusion Criteria:

* Not unresectable stage III disease according to the investigator;
* Subjects with known EGFR sensitive mutations;
* Previous treatment with systemic antitumor therapy for NSCLC;
* Eye inflammation or eye infection not fully treated or conditions predisposing the subject to this.
* History of another malignancy in the last 5 years with the exception of the following: other malignancies cured by surgery alone and having a continuous disease-free interval of 5 years are permitted. Cured basal cell carcinoma of the skin and cured in situ carcinoma of the uterine cervix are permitted.
* Evidence of clinically active interstitial lung disease;
* Known history of testing positive for human immunodeficiency virus (HIV) or known acquired immunodeficiency syndrome (AIDS);
* Inability to comply with protocol or study procedures;
* Any unstable systemic disease (including active infection, active tuberculosis uncontrolled hypertension, unstable angina, congestive heart failure, myocardial infarction within the previous year, serious cardiac arrhythmia requiring medication, hepatic, renal, or metabolic disease);
* A serious concomitant systemic disorder that, in the opinion of the investigator, would compromise the patient's ability to complete the study and may confuse the study results;
* Women who are pregnant or nursing.
* Ingredients mixed with small cell lung cancer patients.

Where it's running

• Sun Yat-sen University Cancer Center
  Guangzhou, Guangdong, China Recruiting

Study contacts

• Principal investigator: Si-Yu Wang, MD — Sun Yat-Sen University Cancer Center
• Study coordinator: Si-Yu Wang, MD
• Email: wangsy@sysucc.org.cn
• Phone: +86 20 87343439

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Natural history of inherited retinal diseases

  This project will test whether color vision problems relate to retinal structure and visual function in people with inherited retinal dystrophies and in people without retinal disease.

  Recruiting Augelux Therapeutics · Wuhan · NCT07085533

• Using bioabsorbable staples to improve surgery outcomes for rectal and lung cancer

  This study is testing if using special dissolvable staples during stomach, colorectal, and lung surgeries can help patients have fewer complications after their operations compared to regular staples.

  Recruiting Phase 3 Shanghai Cingularbio Co. Ltd · Shanghai · NCT06968221

• Evaluating ctDNA diagnostics for Stage III lung cancer

  This study is testing how well blood tests that check for tumor DNA can help people with Stage III lung cancer during and after their treatment.

  Recruiting at 4 sites University Medical Center Groningen · Nice, Nice and 5 other locations · NCT06111807

• Observing the natural history of patients with HPDL mutations

  This study is trying to learn more about people with HPDL mutations and their related mitochondrial diseases by collecting health information and blood samples to see how these conditions change over time.

  Recruiting University of California, San Diego · San Diego, California · NCT05848271

• Understanding diagnostic and prognostic factors in melanoma

  This study is trying to find out how different types of skin growths, like melanoma and benign moles, affect patients by looking at their medical history and collecting blood samples.

  Recruiting at 4 sites Region Skane · Helsingborg, Skåne County and 3 other locations · NCT05446155

• Combining Certolizumab with Chemotherapy and Nivolumab for Treating Lung Cancer

  This study is testing if adding certolizumab to regular chemotherapy and nivolumab can help people with operable stage II-III lung cancer feel better by reducing inflammation and improving treatment results.

  Recruiting at 7 sites Phase 2 Memorial Sloan Kettering Cancer Center · Basking Ridge, New Jersey and 6 other locations · NCT04991025

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.